Shatha Farhan, MD
Internal Medicine · Detroit, MINPI 1740499276
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,224 of the $3,518 with a category attached, or 91.6%. Sanofi-aventis U.S. LLC accounts for 95.6% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $1172.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- National Marrow Donor Program$156
Across 51 payments — averaging $4103.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$53K
- National Marrow Donor Program$40K
- Bristol Myers Squibb$40K
- Deciphera Pharmaceuticals Inc.$35K
- Janssen Research & Development, LLC$23K
- AstraZeneca$19K
What the payments were for
- Speaking & faculty fees$3,22492%
- Travel & lodging$1564%
- Food & beverage$1384%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 2 | $3,362 |
| National Marrow Donor Program | 1 | $156 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUROCK$138
How this compares
$3,518 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 49 | $794,604 |
| PrevymisLetermovir | 21 | $151,601 |
| Cyclosporine | 14 | $3,310 |
| Acyclovir | 86 | $1,981 |
| Tacrolimus | 21 | $1,821 |
| Methylprednisolone | 12 | $459 |
| Penicillin V Potassium | 51 | $342 |
| Omeprazole | 28 | $292 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $223 |
| Oxycodone Hcl | 15 | $191 |
| Azithromycin | 11 | $186 |
| Metoprolol Succinate | 12 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $88 |
| Carvedilol | 13 | $84 |
| Metoprolol Tartrate | 17 | $26 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Detroit
- Saroj NeupaneDetroit$373K
- David StocktonDetroit$306K
- Mervin WolffDetroit$182K
- Philip KuriakoseDetroit$143K
- Ivan HansonDetroit$137K
- Omeralfaroug AdamDetroit$124K
- Jalal MaghfourDetroit$81K
- Ravish ParekhDetroit$68K
- Dipenkumar ModiDetroit$64K
- Garen WolffDetroit$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.